Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

cd29 + Human umbilical cord-derived mesenchymal stem cells and their use in the preparation of drugs for the treatment of skeletal muscle atrophy in high-sugar and high-fat environments

A technology of mesenchymal stem cells and human umbilical cords, applied in bone/connective tissue cells, animal cells, drug combinations, etc., can solve problems of varying degrees, improve hyperlipidemia, increase hyperglycemia, and increase the content of each myotube and the effect of cell number

Active Publication Date: 2021-02-26
JILIN TUO HUA BIOTECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, alterations in skeletal muscle mass in type 2 diabetes occur less predictably and to varying degrees

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • cd29 <sup>+</sup> Human umbilical cord-derived mesenchymal stem cells and their use in the preparation of drugs for the treatment of skeletal muscle atrophy in high-sugar and high-fat environments
  • cd29 <sup>+</sup> Human umbilical cord-derived mesenchymal stem cells and their use in the preparation of drugs for the treatment of skeletal muscle atrophy in high-sugar and high-fat environments
  • cd29 <sup>+</sup> Human umbilical cord-derived mesenchymal stem cells and their use in the preparation of drugs for the treatment of skeletal muscle atrophy in high-sugar and high-fat environments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 CD29 + Isolation of human umbilical cord-derived mesenchymal stem cells

[0033] 1.1 Mix 2ul anti-human CD29 antibody (R&D Systems, US) with 1mg poly-lysine (Sigma) at 4°C, spread it on a 90mm diameter petri dish (Shanghai Jingan Biotechnology Co., Ltd.), and set aside overnight at 4°C .

[0034] 1.2 Aseptic operation, wash the umbilical cord with PBS (Gibco) until there is no blood stain and turns white.

[0035] 1.3 Cut the tissue into small pieces with ophthalmic scissors, cut it longitudinally, and cut the Walton glue into small pieces after removing the blood vessels and umbilical cord skin.

[0036] 1.4 Put a small piece of umbilical cord tissue in a 50ml centrifuge tube, cut it into a muddy shape, add 0.1% collagenase IV (Gibco), digest at 37°C for 2 hours, add an appropriate amount of ɑ-MEM (Gibco) containing 10% fetal bovine serum for culture Mix the solution, centrifuge at 2000g for 10 minutes (L-800R Jiangdong Instruments, China), discard the sup...

Embodiment 2

[0040] Example 2 Examination of surface markers of human umbilical cord-derived mesenchymal stem cells

[0041] 2.1 Take the 5th generation 1×10 6 Cells / ml, 0.1ml / tube in a flow detection tube.

[0042] 2.2 Add directly labeled fluorescent antibodies CD29, CD34, CD45, HLA-DR, CD73, CD90, CD105 (Biolegend, US) and corresponding isotype control antibodies for immunolabeling reaction.

[0043] 2.3 After incubating at 4°C for 20-30 minutes, wash with PBS 1-2 times, and centrifuge to discard the supernatant.

[0044] 2.4 Add 0.5ml PBS buffer to suspend the cells into a single cell suspension.

[0045] 2.5 Use FACSCalibur flow cytometer Cellquset Software analysis software to detect each sample.

[0046] Test results such as Figure 4-9 As shown, the human umbilical cord-derived mesenchymal stem cells of the present invention express the following four mesenchymal stem cell membrane molecules: human leukocyte differentiation antigen CD73, human leukocyte differentiation antigen ...

Embodiment 3

[0047] Example 3 CD29 + Adipogenic differentiation of human umbilical cord-derived mesenchymal stem cells

[0048] 3.1 Select P5 generation of umbilical cord-derived mesenchymal stem cells in good growth state. When the cell fusion rate reaches 80%-90% fusion, trypsinize.

[0049] 3.2 Seed the cells in a six-well plate, about 2.5×10 per well 4 For each cell, add 2ml / well of complete culture medium, and put them in 37℃, 5% CO 2 Cultured in the incubator and hypoxic incubator for 24h.

[0050] 3.3 After 24 hours, remove the old culture medium, and add lipid induction solution (α-MEM medium supplemented with 10% fetal bovine serum, 0.6mM IBMX, 12mg / L insulin, 10 -5 M dexamethasone and 250 μM indomethacin), induced for 21 days.

[0051] 3.4 Discard the medium in the culture plate, rinse twice with PBS, add 4% neutral formaldehyde, fix for 30min, and absorb the fixative.

[0052] 3.5 Add the oil red O staining solution that is now filtered, stain for 30 minutes, wash with PBS ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CD29<+> human umbilical cord source mesenchymal stem cell and use thereof in the preparation of a drug for treating skeletal muscle atrophy in high-sugar and high-fat environments. The CD29<+> human umbilical cord source mesenchymal stem cell represents the following mesenchymal stem cell cytomembrane molecules: a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90, a human leukocyte differentiation antigen CD105 and a human leukocyte differentiation antigen CD29. According to the CD29<+> human umbilical cord source mesenchymalstem cell, the hyperlipidemia and hyperglycemia of a db<- / -> mouse can be obviously improved, muscle fiber cross sections of soleus and gastrocnemius muscle of the db<- / -> mouse can be increased, andthe contents and cell number of each myotube are increased, so that the symptoms of the skeletal muscle atrophy of the db<- / -> mouse are improved. According to the CD29<+> human umbilical cord sourcemesenchymal stem cell, the theoretical foundation and experiment basis are laid for the subsequent research and development of the drug for treating skeletal muscle atrophy in the high-sugar and high-fat environments, and the CD29<+> human umbilical cord source mesenchymal stem cell has wide application prospects.

Description

technical field [0001] The invention relates to the field of mesenchymal stem cells, specifically a CD29 + Human umbilical cord-derived mesenchymal stem cells and their use in the preparation of drugs for treating skeletal muscle atrophy in high-sugar and high-fat environments. Background technique [0002] Skeletal muscle mass and integrity are critical for proper function of the musculoskeletal system and efficient nutrient uptake and storage. Skeletal muscle tissue is the largest metabolically active tissue in the body, the major site of glucose metabolism and a fuel reservoir for other organs under pathological conditions. Muscle atrophy not only occurs with many common diseases, such as cancer, renal / heart failure, sepsis, muscle genetic diseases and neurodegenerative diseases, etc., but also occurs in healthy individuals, such as during the immobilization of a broken leg, during bed rest . The major determinants of adult muscle mass are exogenous essential amino aci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/0775A61K35/28A61P21/00A61P3/06A61P3/10
Inventor 唐静
Owner JILIN TUO HUA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com